IV Infliximab, a monoclonal antibody, has emerged as an efficient treatment with many clinical benefits, such as quick disease activity reduction and IBD patient life quality improvement. However, drug development of infliximab using weight-based dosing of MAbs without consideration of…
Dr. Marla Dubinsky discusses the unique, personalized, and integrated care offered for children at the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center in a video posted by Mount Sinai Health System. Dr. Dubinsky starts by discussing some…
Ankylosing Spondylitis Awareness Month is observed every April. This month is dedicated to raising awareness and recognizing arthritis and other associated illnesses such as ankylosing spondylitis. What is Ankylosing Spondylitis? Ankylosing spondylitis, or AS, is a form of arthritis that…
The right dose of medicine is crucial when it comes to the treatment process. For patients with inflammatory bowel disease (IBD), the wrong dose can cause patients to lose response to Infliximab (IFX), a highly effective drug used to treat…
Precision dosing focuses on the individualization of drug treatment regimens based on drug attributes, pharmacokinetic/pharmacodynamic variability, disease state characteristics, and patient-specific factors. Before precision dosing, pharmaceutical medicine adopted a one-size-fits-all approach that focused on dosing regimens based on the average…
Inflammatory bowel disease (IBD) describes a group of disorders that cause the intestines to become inflamed. There are two main types of IBD: ulcerative colitis and Crohn’s disease. These two types of IBD are increasingly prevalent, relapsing and remitting inflammatory…
Inflammatory bowel disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of the digestive tract. The two main types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). While there is currently no cure…
Inflammatory bowel disease (IBD), is primarily composed of Crohn’s disease (CD) and ulcerative colitis (UC) and affects as many as 1.6 million Americans, with approximately 30,000 new cases diagnosed each year. Both are marked by an abnormal response by the…
Model-informed precision dosing (MIPD) involves modeling and simulation to predict the necessary drug dose for a given patient based on their individual characteristics that are most likely to improve efficacy and/or lower toxicity in comparison to traditional dosing. The standard…
The Institute for Clinical and Economic Review (ICER) systematically reviewed and synthesized existing evidence from clinical studies to assess the comparative clinical effectiveness for targeted immune modulators (TIMs) for moderate-to-severe ulcerative colitis (UC). ICER’s draft scoping document was developed with…
